Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus SULAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER versus SULAR.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs SULAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
Nisoldipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle. This leads to vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand.
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
10-20 mg orally once daily; maximum 60 mg/day.
None Documented
None Documented
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Terminal half-life of 24-50 hours, mean ~34 hours; extended in elderly and hepatic impairment, dose adjustment may be needed
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Renal: 50-60% as metabolites, 10% as unchanged drug; Fecal: ~35%; Biliary: <5%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker